Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cancer immunotherapy: broadening the scope of targetable tumours.

Open biology - 1 Jun 2018

van den Bulk Jitske, Verdegaal Els Me, de Miranda Noel Fcc

Abstract excerpt

Cancer immunotherapy has experienced remarkable advances in recent years. Striking clinical responses have been achieved for several types of solid cancers (e.g. melanoma, non-small cell lung cancer, bladder cancer and mismatch repair-deficient cancers) after treatment of patients with T-cell checkpoint blockade therapies. These have been shown to be particularly effective in the treatment of cancers with high...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Antineoplastic Agents, Immunological
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Molecular Targeted Therapy

Share to Mutation

Share to Neoplasms

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 29875199
DOI: 10.1098/rsob.180037
PMCID: PMC6030119

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cancer immunotherapy: broadening the scope of targetable tumours.PMID 29875199Read ↗

New emerging targets in cancer immunotherapy: the role of neoantigensSemantic proximity Read ↗

Progress in Neoantigen Targeted Cancer ImmunotherapiesSemantic proximity Read ↗

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.Semantic proximity Read ↗

Neoepitopes as Cancer Immunotherapy Targets: Key Challenges and OpportunitiesSemantic proximity Read ↗

Targeting Neoepitopes to Treat Solid Malignancies: ImmunosurgerySemantic proximity Read ↗

Boosting Antitumor Immunity with an Expanded Neoepitope Landscape.Semantic proximity Read ↗

Identification and Targeting of Mutant Peptide Neoantigens in Cancer ImmunotherapySemantic proximity Read ↗

A Nobel Prize‐worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigensSemantic proximity Read ↗

The double-edged sword of cancer mutations: exploiting neoepitopes for the fight against cancer.Semantic proximity Read ↗

Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens.Semantic proximity Read ↗

Emerging Strategies in TCR-Engineered T CellsSemantic proximity Read ↗

Neoantigen-based cancer immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.